Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
| Autor: | Carmen Martínez Chamorro, Juan Bayo, María Reyes Abad-Sazatornil, Javier Letellez, Ainhoa Arenaza, Virginia Reguero, Jose María Guinea de Castro, Jesus García Mata, Antonio Salar, Josefa León |
|---|---|
| Přispěvatelé: | Servicio de Farmacia. Hospital Universitario de Fuenlabrada |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Healthcare use Injections Subcutaneous Efficiency indicators España Efficiency Health administration 03 medical and health sciences Healthcare capacity Eficiencia 0302 clinical medicine Trastuzumab Product Label medicine Humans Hospital pharmacy 030304 developmental biology 0303 health sciences Resource optimization business.industry Health Policy lcsh:Public aspects of medicine Subcutaneous lcsh:RA1-1270 Healthcare quality Hospitals Cancer treatment Cross-Sectional Studies Inyecciones Subcutáneas Spain 030220 oncology & carcinogenesis Emergency medicine Rituximab business Intravenous Resource utilization medicine.drug Research Article |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 21, Iss 1, Pp 1-10 (2021) Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| Popis: | Background Subcutaneous (SC) versus intravenous (IV) administration is advantageous in terms of patient convenience and hospital efficiency. This study aimed to compare the effect of optimizing the processes involved in SC versus IV administration of rituximab and trastuzumab on hospital capacity and service quality. Methods This cross-sectional resource utilization study interviewed oncologists, hematologists, nurses, and pharmacists from 10 hospitals in Spain to estimate changes in processes associated with conversion from IV to SC rituximab and trastuzumab, based on clinical experience and healthcare use from administrative databases. Results Efficient use of SC formulations increased the monthly capacity for parenteral administration by 3.35% (potentially increasable by 5.75% with maximum possible conversion according to the product label). The weekly capacity for hospital pharmacy treatment preparation increased by 7.13% due to conversion to SC formulation and by 9.33% due to transferring SC preparation to the cancer treatment unit (potentially increasable by 12.16 and 14.10%, respectively). Monthly hospital time decreased by 33% with trastuzumab and 47% with rituximab. In a hypothetical hospital, in which all processes for efficient use of SC rituximab and/or trastuzumab were implemented and all eligible patients received SC formulations, the estimated monthly capacity for preparation and administration increased by 23.1% and estimated hospital times were reduced by 60–66%. Conclusions Conversion of trastuzumab and rituximab to SC administration could improve the efficiency of hospitals and optimize internal resource management processes, potentially increasing care capacity and improving the quality of care by reducing time spent by patients at hospitals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|